Nasal mucosa

Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19

Retrieved on: 
Tuesday, September 13, 2022
Securities Exchange Act of 1934, Therapy, Risk, U.S. Securities and Exchange Commission, Safety, Vertigo, Allergen, COVID-19, Nasal spray, Virus, Securities Act of 1933, Severe acute respiratory syndrome coronavirus 2, Securities & Exchange Commission of Pakistan, Hearing loss, Company, Population, Tinnitus, Degenerative disease, Nose, Person, Forward-looking statement, Patient, Infection, OTC, Viral load, Terminology, Cell, Annual report, Allergic rhinitis, NASDAQ, RNA, Nasal mucosa, SEC, Pharmaceutical industry, Vaccine

In the COVAMID trial, the COVID-19 patients are randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo (Bentrio minus its key mineral component), or no treatment, followed by a 10-day observation phase.

Key Points: 
  • In the COVAMID trial, the COVID-19 patients are randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo (Bentrio minus its key mineral component), or no treatment, followed by a 10-day observation phase.
  • Altamira expects to announce top-line data from the COVAMID trial during the fourth quarter of 2022.
  • For more info, visit: https://altamiratherapeutics.com/our-products/bentrio
    Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs.
  • All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties.

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
GLOBE, Death, SEC, Clinical trial, Prevalence, Refrigeration, Home After Three Months Away, Research, Degenerative disease, Omicron, WHO, Animal, Food, Immune system, HPV, Disease, Primate, Risk, Sale, Patent, Respiratory syncytial virus, Immunoglobulin A, Safety, Nasal mucosa, Webcast, Gastroenteritis, Ilie Floroiu, Duke University, COVID-19 testing, Ageing, Compliance, Food and Drug Administration, COVID-19, Program, TLR3, Vaccine, Coronavirus, Vaccination, Report, HCT, Quality control, Science Translational Medicine, Severe acute respiratory syndrome coronavirus 2, FDA, Vomiting, Immunoglobulin G, RSV, Injury, Saliva, NASDAQ, World, Tablet, Diarrhea, Adult, Pharmaceutical industry, Online gambling, Norovirus, Vaxart

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- In its business update today for the second quarter of 2022, Vaxart, Inc. (NASDAQ: VXRT) said it has begun working on vaccine candidate constructs that directly target new omicron variants of concern and is preparing to release top-line data in the third quarter of 2022 from its Phase II COVID-19 testing of a Wuhan strain vaccine construct.

Key Points: 
  • The Companyreported a net loss of$29.4 millionfor the second quarter of 2022, compared to$16.1 million for the second quarter of 2021.
  • Research and development expenses were$19.9 millionfor the second quarter of 2022, compared to$10.7 million for the second quarter of 2021.
  • General and administrative expenses were $9.3 million for the second quarter of 2022, compared to $5.2 million for the second quarter of 2021.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the second quarter of 2022 today, beginning at 4:30 p.m.

Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

Retrieved on: 
Monday, August 1, 2022
Virus, Nasal spray, Infection, Severe acute respiratory syndrome coronavirus 2, Nasal mucosa, U.S. Securities and Exchange Commission, Allergic rhinitis, Degenerative disease, Hearing loss, Forward-looking statement, Union, SEC, Securities & Exchange Commission of Pakistan, Risk, Person, Securities Act of 1933, Securities Exchange Act of 1934, Marketing, Therapy, Safety, COVID-19, NASDAQ, Tinnitus, Cell, Company, Nose, Patient, Annual report, Terminology, Allergen, OTC, Population, RNA, Pharmaceutical industry, Vaccine, EU

COVAMID is a randomized, placebo controlled clinical trial to evaluate the safety, tolerability, and efficacy of Bentrio.

Key Points: 
  • COVAMID is a randomized, placebo controlled clinical trial to evaluate the safety, tolerability, and efficacy of Bentrio.
  • The primary efficacy endpoint will be the mean cycle threshold improvement in the customary RT-PCR test for COVID-19, i.e.
  • In the COVAMID trial, patients are randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo (Bentrio minus its key mineral component), or no treatment, followed by a 10-day observation phase.
  • For more info, visit: https://altamiratherapeutics.com/our-products/bentrio
    Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs.

New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron

Retrieved on: 
Friday, June 3, 2022
Injury, Vaxart, Gamma, Infection, Coronavirus, Company, Research, Quality control, N, Patent, RSV, Report, Immunoglobulin G, Respiratory syncytial virus, Immunoglobulin A, Vaccine, Serum, FDA, Risk, GLOBE, COVID-19, Nasal mucosa, Tablet, Compliance, Antibody, Beta, NASDAQ, SAN, Alpha, Severe acute respiratory syndrome coronavirus 2, HPV, Clinical trial, Refrigeration, TLR3, Norovirus, VXA, Safety, Pharmaceutical industry, Omicron

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant.

Key Points: 
  • A broadly cross-reactive vaccine may be the most effective way to protect against current and future variants, said Dr. Sean Tucker, Vaxarts SVP and Chief Scientific Officer.
  • We developed an Omicron specific vaccine candidate and compared it with our original Wuhan strain vaccine candidate that is currently in Phase II clinical trials.
  • The data reported today are from a study in which the S-only Wuhan and Omicron vaccine candidates were compared in a hamster challenge model.
  • Both vaccines produced antibody responses to the S protein of Omicron, with the Omicron candidate slightly better at making serum IgG antibodies to the matched protein
    These findings demonstrate that in this preclinical model both vaccine candidates protect against the Omicron variant.

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

Retrieved on: 
Wednesday, May 11, 2022
The Blue Knight, Hospital, BARDA, Nasal mucosa, BLUE, Company, GLOBE, Development, Human services, Biomedical Advanced Research and Development Authority, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Fever, Office of Inspector General, U.S. Department of Health and Human Services, Virus, Human, Johnson & Johnson, Severe acute respiratory syndrome coronavirus 2, Family, Rhinovirus, Conference, CEO, Nose, Research, Interview, ENA, Epithelium, Johnson & Johnson COVID-19 vaccine, Risk, Pharmaceutical industry, Vaccine, H1N1

ENA Respiratory is the first Australian company to be selected to join Blue Knight.

Key Points: 
  • ENA Respiratory is the first Australian company to be selected to join Blue Knight.
  • Blue Knight offers a scientific and technological ecosystem for innovative, early-stage companies to develop strategically aligned technologies that aim to combat health threats and emerging infectious diseases.
  • As a Blue Knight company, ENA Respiratory will benefit from mentorship from experts from BARDA, the Johnson & Johnson Family of Companies, and a global network of innovators who could provide critical insight and support throughout INNA-051 development.
  • ENA Respiratorys self-administered nasal spray INNA-051 product is designed with the aim to stimulate the innate immunity in the nose, which is the preferential site of initial infection and replication of most respiratory viruses.

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
Infection, Antibody, COVID-19, Respiratory syncytial virus, Home After Three Months Away, Report, Volunteering, Immunoglobulin A, NASDAQ, GLOBE, BioRxiv, RSV, Tablet, Safety, Research, Refrigeration, Coronavirus, Clinical trial, Risk, FDA, Norovirus, Injury, Compliance, Patent, Alpha, Ageing, Severe acute respiratory syndrome coronavirus 2, Beta, Vaccine, TLR3, Sale, HPV, Quality control, SEC, Serum, Vaccination, Technology, Gamma, Nasal mucosa, Pharmaceutical industry, Video game, Vaxart

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.

Key Points: 
  • Results from Vaxarts Phase IB trial of its norovirus vaccine candidate in elderly subjects are expected in the second quarter of 2022.
  • The Companyreported a net loss of$25.1 millionfor the first quarter of 2022, compared to$16.0 million for the first quarter of 2021.
  • Research and development expenses were$18.2 millionfor the first quarter of 2022, compared to$10.1 million for the first quarter of 2021.
  • General and administrative expenses were$6.7 millionfor the first quarter of 2022, compared to$5.9 million the first quarter of 2021.

Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement

Retrieved on: 
Tuesday, March 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Epilepsy, MET, Nanotechnology, Technology, University, UCL School of Pharmacy, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., CNS, Bupivacaine, Private Securities Litigation Reform Act, CBD, FDA, University of Strathclyde, Post-traumatic stress disorder, CFO, Central nervous system disease, COVID-19, Animal, Nature, Degenerative disease, Security (finance), NASDAQ, University College London, Lists of diseases, Investigational New Drug, IND, Cell, Company, PTSD, CEO, Severe acute respiratory syndrome coronavirus 2, Virus, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Industry, Drug Quality and Security Act, Securities Act of 1933, Coronavirus, Pain management, RATS, Nasal mucosa, Pharmaceutical industry, Vaccine, Risk management, Pharmacy, AnQlar™, Nanomerics, Virpax Pharmaceuticals, ANQLAR™, NANOMERICS, VIRPAX PHARMACEUTICALS

Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management as well as PTSD, CNS disorders and anti-viral indications, expanded its exclusive license agreement for AnQlar with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization.

Key Points: 
  • Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management as well as PTSD, CNS disorders and anti-viral indications, expanded its exclusive license agreement for AnQlar with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization.
  • This assists us with the transition of AnQlar to a potential over-the-counter designation by the FDA, stated Christopher M. Chipman, CFO and Secretary of Virpax.
  • Obtaining the worldwide rights to AnQlar is consistent with our global business model and puts the company in a stronger position to pursue strategic alliances or enterprise opportunities for this product candidate, commented Anthony P. Mack, Chairman & CEO of Virpax.
  • AnQlar (GCPQ) is a positively-charged chitosan derivative that binds electrostatically to negatively charged viruses such as SARS-CoV-2 and influenza.

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

Retrieved on: 
Tuesday, March 15, 2022
Viral load, Urinary tract infection, Human, GLOBE, RSV, Patient, United Kingdom, Risk, Nasal mucosa, COVID-19, ENA, Safety, Hospital, Interview, Epithelium, Fever, PHASE 2, CEO, Incidence, Severe acute respiratory syndrome coronavirus 2, Virus, Post-exposure prophylaxis, Rhinovirus, Infection, Liver, Vaccine, Pharmaceutical industry, H1N1

The study will enroll up to 123 participants.

Key Points: 
  • The study will enroll up to 123 participants.
  • Efficacy is being assessed as the reduction of total viral load by RT-qPCR and total symptoms score in treated versus placebo participants.
  • The study also will evaluate whether the nasal spray reduces the magnitude and duration of SARS-CoV-2 nasal shedding, to understand potential broader public health benefits.
  • INNA-051 was found to be well-tolerated in a Phase 1 study, and complete Phase 1 results are expected soon.

Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets

Retrieved on: 
Friday, March 4, 2022
Risk, Viral load, Degenerative disease, Hearing loss, Terminology, Infection, Patient, Pollen, Vertigo, Virus, Prevalence, Forward-looking statement, RNA, Securities Exchange Act of 1934, Annual report, U.S. Securities and Exchange Commission, Nasal spray, Nasal mucosa, Nasdaq, Founder, Growth, Therapy, Anemia, Tinnitus, Allergen, Person, Securities & Exchange Commission of Pakistan, Company, SEC, Allergy, Securities Act of 1933, CEO, Good, Cell, Allergic rhinitis, Nose, Semaphore, Severe acute respiratory syndrome coronavirus 2, Agreement, NASDAQ, Pharmaceutical industry, Mainland China, Territory, Nuance

Under the terms of the Agreement, Altamira will initially supply Bentrio(TM) to Nuance.

Key Points: 
  • Under the terms of the Agreement, Altamira will initially supply Bentrio(TM) to Nuance.
  • In a second stage, Nuance will assume local production of the product for the Territory upon certain milestones.
  • Once Nuance assumes local production of Bentrio(TM), it will pay to Altamira a staggered royalty on net sales in the Territory at a high-single to low-double-digit percentage.
  • "We are excited to greatly expand the distribution of Bentrio and further enlarge our footprint in Asia through this strategic collaboration with Nuance," said Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO.

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, February 24, 2022
Risk, Compliance, Ionel Floroiu, COVID-19, Company, Severe acute respiratory syndrome coronavirus 2, TLR3, General counsel, HPV, Phase II, Research, Plant, Coronavirus, Quality control, Home After Three Months Away, D&O, Sale, Safety, Immunity, Biotechnology, Stanford University, VXA, Immunoglobulin A, D, Serum, NASDAQ, Refrigeration, Microorganism, Volunteering, Antibody, Fortune 500, Norovirus, Vaccine, Alpha, Duke University, GLOBE, Omicron, Report, Gamma, Cell Host & Microbe, RSV, Clinical trial, Respiratory syncytial virus, Ageing, Tablet, Acquisition, BioRxiv, FDA, Beta, Nasal mucosa, Patent, Injury, SEC, Cryptocurrency, Pharmaceutical industry, Construction, Aquaculture, Vaxart, Laninamivir, Phase

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the fourth quarter and full year 2021, reporting forward momentum for the Company, including its oral norovirus and COVID-19 vaccine candidates.

Key Points: 
  • During the fourth quarter of 2021, Vaxart began Phase II clinical trials of its oral tablet COVID-19 vaccine in the U.S. Vaxart dosed its first subject in late October 2021.
  • The Companyreported a net loss of$20.8 millionfor the fourth quarter of 2021, compared to$13.9 millionfor the fourth quarter of 2020.
  • Research and development expenses were$15.5 millionfor the fourth quarter of 2021, compared to$8.6 millionfor the fourth quarter of 2020.
  • General and administrative expenses were$5.8 millionfor the fourth quarter of 2021, compared to$5.1 millionfor the fourth quarter of 2020.